Cloud DX Signs Contract with US University Nursing School

Cloud DX supplies Virtual Care and Remote Patient Monitoring hardware and services to educate the next generation of nurses and nurse practitioners in Oregon

News in Summary

Cloud DX has signed an 18 month contract with University School of Nursing in Oregon
Company to supply its Connected Health™ hardware, services, and connectivity to educate nursing students on best-in-class virtual care systems
This is the ninth contract executed or deployed in Q1 2022 for Cloud DX

KITCHENER, ON / ACCESSWIRE / March 8,2022 /Cloud DX (TSXV:CDX) (OTC:CDXFF), Cloud DX, a leading Virtual Care platform, announces today the signing of an 18 month contract as the exclusive vendor for Telemedicine and Remote Patient Monitoring equipment, services, and connectivity with a University Nursing School in Portland, Oregon.

This agreement demonstrates key competitive advantages of the company's Connected Health™ offering: including easy-to-use medical devices, intuitive and flexible user interfaces, and exceedingly high user satisfaction. Two hospitals using Cloud DX platform, The Ottawa Hospital and Kingston Health Science Center, released results of recent user surveys. Each indicated that over 95% of users were satisfied or very satisfied with Connected Health™.

"Patients love our Connected Health platform and Healthcare educators do too," says Robert Kaul, CEO and Founder of Cloud DX. "Our platform lowers the burden on healthcare staff and enables nurses to be closer and more connected to their patients. With a closer circle of care, our virtual care and remote monitoring solutions improve patient outcomes, in turn reducing hospital re-admissions and lowering system costs. Agreements such as this one ensure upcoming generations of nursing students are learning to leverage Telemedicine and Remote Patient Monitoring to make healthcare better, for everyone, the Cloud DX way."

About Cloud DX

Accelerating virtual healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health^TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers." In 2021, Cloud DX became an exclusive partner to Medtronic Canada.

Cloud DX Investor Site:https://ir.clouddx.com/overview/default.aspx

^{Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.}

Social Links

Twitter https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/

For media inquiries please contact:

Janine Scott
Marketing Lead
888-543-0944
janine.scott@CloudDX.com

For investor inquiries please contact:

Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@CloudDX.com

SOURCE:Cloud DX Inc.

View source version on accesswire.com:
https://www.accesswire.com/692054/Cloud-DX-Signs-Contract-with-US-University-Nursing-School

News Provided by ACCESSWIRE via QuoteMedia

Cloud DX TSXV:CDX Emerging Tech Investing

CDX:CA

Syntheia Set to Enhance Customer Communication with Its AI-Powered Virtual Assistant

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, a Canadian leader in conversational AI, announces that its innovative SaaS platform, designed to transform how businesses manage inbound telephone calls is set to launch in January of 2025. Leveraging advanced Natural Language Processing (NLP), Syntheia's virtual assistants enhance communication and efficiency targeting small and medium businesses in this large global marketplace.

" Our mission is to eliminate as many inefficiencies as we can with managing inbound calls that small to medium-sized businesses face utilizing the power of AI" said Tony Di Benedetto, CEO of Syntheia. "With AI-driven virtual assistants, we provide these businesses with tools to improve customer satisfaction while reducing operational costs. We are gearing up now for commercial launch in January of 2025, less than 8 weeks away."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that its Chief Scientific Officer, Dr. Len Pagliaro, has been invited to showcase Sona's developing Targeted Hyperthermia Therapy ("THT") cancer treatment today at the Nanotechnology Characterization Laboratory ("NCL"). Sona will be one of six commercial and academic collaborators to present its research at the NCL's 20th anniversary "Advancing Medical Applications of Cancer Nanotechnology" symposium. Sona's subsidiary was previously selected for the NCL Assay Cascade Program, the premier program in the World for bringing nanomaterials through critical preclinical stages and facilitating regulatory review, in which Sona's materials were assessed for biocompatibility. The NCL was established by the National Cancer Institute ("NCI") to accelerate the progress of nanomedicine by providing preclinical characterization and safety testing of nanoparticles. The NCL is a collaborative effort between NCI, the U.S. Food and Drug Administration ("FDA"), and the National Institute of Standards and Technology.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Sona Nanotech Issued Patent and Appoints New Board Member

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the issuance of U.S. Patent No. 12117447 by the U.S. Patent and Trademark Office to the Company, entitled, "Metal Nanoparticles and Methods of Making Same". This patent covers the Company's proprietary process for manufacturing gold nanorods without the use of the toxic substance, cetyltrimethylammonium bromide ("CTAB"), which typically carries significant cytotoxic and genotoxic risks.

The Company is also pleased to announce the appointment of Mr. Wayne Myles, KC, FIIC, to its board of directors. An active investor and entrepreneur, Mr. Myles has served as lead counsel and strategic business advisor on more than 100 domestic and international acquisitions and sales, financings, government and regulatory affairs and licensing mandates. He has significant and diverse experience as a director of public and private companies. He also has been recognized with numerous professional achievements, distinctions and awards, including being named as one of "Canada's Top 25 Most Influential Lawyers' by Canadian Lawyer Magazine."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Cloud DX Signs Contract with US University Nursing School

Latest News

Latest Press Releases

Related News

TOP STOCKS